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AbstrAct
Long non-coding RNAs are important regulators of gene expression and 
signaling pathways. The expression of long ncRNAs is dysregulated in cancer and 
other diseases. The identification and characterization of long ncRNAs is often 
challenging due to their low expression level and localization to chromatin. Here, 
we identify a functional long ncRNA, PARROT (Proliferation Associated RNA and 
Regulator Of Translation) transcribed by RNA polymerase II and expressed at a 
relatively high level in a number of cell lines. The PARROT long ncRNA is associated 
with proliferation in both transformed and normal cell lines. We characterize the long 
ncRNA PARROT as an upstream regulator of c-Myc affecting cellular proliferation and 
translation using RNA sequencing and mass spectrometry following depletion of the 
long ncRNA. PARROT is repressed during senescence of human mammary epithelial 
cells and overexpressed in some cancers, suggesting an important association with 
proliferation through regulation of c-Myc. With this study, we add to the knowledge 
of cytoplasmic functional long ncRNAs and extent the long ncRNA-Myc regulatory 
network in transformed and normal cells.
INtrODUctION
The non-coding portion of the mammalian genome 
is pervasively transcribed resulting in the expression 
of thousands of mRNAs and long non-coding RNAs 
(ncRNA) [1, 2]. Although only a small number of long 
ncRNAs have been characterized to date they have 
been shown to be involved in almost every level of the 
gene expression program such as transcription, mRNA 
processing and translation [3]. Long ncRNAs are 
involved in the development of a variety of disorders 
such as cancer and neurodegenerative disorders [3, 4]. 
Long ncRNAs mediating regulation of tumor-suppressors 
and oncogenes through various mechanisms have been 
described [5-7]. The long ncRNAs lincRNA-p21 [8]; 
Pint [9]; PR-lncRNA-1 and PR-lncRNA-10 [5] are 
regulated by the tumor suppressor p53 and are involved in 
mediating its effects [6, 10]. Using a different mechanism, 
the long ncRNA-RB1 is co-expressed with RB1 from a 
bidirectional promoter and links RB1 transcription to the 
transcription of another tumor suppressor, Calreticulin, 
with effects on immunogenic cell death [7]. On the other 
hand, the long ncRNA ANRIL acts as an oncogene. 
ANRIL interacts with components of both the PRC1 and 
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PRC2 complexes and mediates the silencing of the INK4a/
ARF locus encoding tumor-suppressor genes that regulate 
cell cycle-progression and senescence [11]. Depletion of 
ANRIL leads to reduced proliferation and the long ncRNA 
is up-regulated in prostate cancer and leukemia further 
supporting an oncogenic role [12, 13].
The Myc family of proteins is a group of basic 
helix-loop-helixl eucine zipper transcription factors, 
one of the most studied classes of proteins associated 
to cancer. There are three members of the Myc family, 
c-Myc, n-Myc and l-Myc [14], all three functioning in 
a similar manner but with expression differences across 
cancers types. For instance, c-Myc is overexpressed in 
both blood-borne and solid tumors; n-Myc is expressed 
mostly in neural tumors; and l-Myc is overexpressed 
in small cell lung carcinomas [14-16]. Overall, many 
human cancers show increased expression of Myc. The 
transcription factor c-Myc regulates the transcription 
of at least 15% of the genes in the human genome with 
the help of its heterodimer partner MAX [17]. c-Myc is 
involved in many biological processes such as cell cycle, 
differentiation and protein synthesis [17, 18]. Since c-Myc 
is upregulated in many human cancers it is subject to 
intense investigation for cancer treatment [15, 16]. Several 
studies have shown that c-Myc regulates the expression 
of long ncRNAs, and that some of these transcripts can 
participate in the transcriptional functions mediated by 
c-Myc [19-22]. Long ncRNA-mediated regulation of 
translation of c-Myc has also been suggested [23, 24].
Here, we report that PARROT (proliferation 
associated RNA and regulator of translation) is a long 
ncRNA with a dynamic expression range across both 
transformed and normal cells that contributes to cellular 
proliferation in senescence and cancer and is associated to 
translation efficiency in HeLa cells. Using transcriptomic 
and proteomic approaches we identify PARROT as an 
upstream regulator of c-Myc. Depletion of PARROT leads 
to a depletion of c-Myc both at the mRNA and protein 
levels with subsequent effects on cellular growth and 
proliferation.
rEsULts
Differential promoter activity drives ncrNA 
expression
Long ncRNAs are often expressed at a low level, 
complicating the further analysis of their transcriptional 
regulation and biological functions. Using available 
data for HeLa and HEK293 cells we identified the long 
ncRNAs with Pol(II) at their promoter in at least one 
of the two cell lines, to identify actively expressed and 
highly abundant long ncRNAs (Figure 1A). To reduce 
the number of candidates and to increase the probability 
of identifying long ncRNAs that are functional also 
in non-transformed cells, we restricted the analysis 
to long ncRNAs suggested to be functional based on 
their expression in keratinocytes and responsiveness to 
12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced 
differentiation of keratinocytes [25]. This results in a 
set of 21 long ncRNAs that show Pol(II) binding at their 
promoters in at least one of the cell lines (Figure 1B). 
While six long ncRNAs have defined Pol(II) peaks in both 
cell lines, most (15) are clearly bound specifically by high 
levels of Pol(II) in one cell line only as shown in Figure 
1C, which is recapitulated in the expression level of the 
long ncRNAs in the respective cell lines, reflecting the 
tissue-specific properties of long ncRNAs that have mostly 
been reported for lowly expressed long ncRNAs (Figure 
1D). While the generally low expression level of long 
ncRNAs is believed to result from post-transcriptional 
regulation, we asked whether the regulation of a highly 
expressed long ncRNA is indeed occurring at the promoter 
level by cloning an upstream region of the annotated 
transcript into a reporter vector (Figure 1E). We observed 
a high induction of PARROT expression in HeLa cells 
(Figure 1F), while essentially no transcription occurred in 
HEK293 cells (Figure 1G). Further characterization of the 
promoter by cloning of fragments of 166, 222, 298 and 
404 base pairs, respectively, upstream of the transcription 
start site (TSS) in the same reporter assay identified a short 
promoter region mediating the tissue-specific expression 
of PARROT (Figure 1E-1G), similar to what is often 
observed for protein coding genes.
PArrOt is a spliced non-coding rNA localized 
to the cytoplasm
To determine the cellular distribution of PARROT 
we subjected HeLa cells to cellular fractionation, 
separating the cells into cytoplasmic, nucleoplasmic and 
chromatin fractions [26]. We can show the localization 
of the processed form of PARROT to be primarily 
cytoplasmic (Figure 2A) suggesting functions different 
from regulation of transcription as has been reported for 
many nuclear localized long ncRNAs. We obtained the 
transcript profile of PARROT from chromatin-associated 
RNA using RNA sequencing (RNA-seq) with random 
primers and from whole cells using oligod(T) primers 
[27]. The transcriptome profile shows a very long primary 
transcript associated to chromatin and a polyadenylated, 
two-exonic processed transcript with a cytoplasmic 
localization as the spliced transcript form (Figure 2B), 
suggesting that PARROT might have dual functions as a 
long ncRNA in the nucleus as the primary transcript and 
in the cytoplasm as the processed transcript.
To confirm that the annotation of PARROT as a 
non-coding RNA is correct, we cloned the full-length 
processed transcript and synthesized RNA in vitro from 
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a T7 promoter. In vitro translation assay analysis did 
not show the presence of any peptide translated from 
the long ncRNA sequence (Figure 2C). The localization 
of PARROT in polysome profiling experiments as 
determined by quantitative PCR (qPCR) of individual 
fractions is also suggestive of a non-coding function 
(Figure 2D). Furthermore, we confirmed that no peptides 
corresponding to the sequence of PARROT are detected 
in proteogenomic studies [28], as well as absence of 
association to ribosomes in ribosome profiling studies 
from HeLa [29].
PArrOt regulates proliferation and translation
To assess the function of PARROT we used siRNAs 
for knock-down in different cell lines. Following knock-
down in HeLa cells (Figure 3A) a reduction in cell growth 
was observed using crystal violet staining (Figure 3B) 
that could not be assigned to apoptosis using a number 
of available assays (not shown). To address effects on 
migration, in addition to cell growth, we used A549 cells. 
A549 cells display reduced migration ability following 
knock-down of PARROT (Figure 3C). The effect on 
cellular migration is comparable to knock-down of 
SNAI1, a known regulator of cellular migration (quantified 
from three independent experiments in Figure 3D) [30], 
demonstrating a general function of PARROT in several 
cell lines and effects on both cell growth and migration. 
Due to the cytoplasmic localization of PARROT and its 
association to low-molecular weight polysome profile 
fractions, we propose that PARROT could have a 
regulatory function in translation or mRNA stability. To 
address this, we determined the effect of knock-down on 
general translation using a puromycin based translation 
assay. We see a markedly reduced translation observed in 
general upon knock-down of PARROT, as determined by 
puromycin incorporation and western blot of the newly 
synthesized protein (Figure 3E). The Ponceau S staining 
is used as a loading control showing total protein loaded 
Figure 1: Differential promoter activity drives PArrOt expression. A. Pol(II) association to ncRNAs in HeLa and HEK293 
cells. b. Pol(II) association to ncRNAs in HeLa and HEK293 cells differentially expressed upon keratinocyte differentiation. c. Snapshot 
from the genome browser of Pol(II) association to PARROT in HeLa and HEK293 cell line. D. Relative expression of PARROT in HeLa 
and HEK293 cells measured by qPCR. (E., F., G.) PARROT promoter region was cloned upstream of the Luciferase in pGL3 vector. E. 
Graphical representation of the inserts used. F.-G. Luciferase reporter assay. The Firefly luciferase vectors were cotransfected with a Renilla 
luciferase vector (pRL-TK) for transfection control in HeLa F. and HEK293 cells G. 
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in each lane, and three independent experiments were 
quantified to determine statistical significance (Figure 3F).
PArrOt is an upstream regulator of Myc
To determine the molecular mechanism by which 
PARROT exerts its effect on the cellular phenotype we 
depleted it using siRNAs and performed RNA sequencing 
of polyadenylated transcripts in HeLa cells. This analysis 
reveals that the depletion of PARROT affects the 
expression of 331 genes of which 181 are upregulated and 
150 are downregulated. Gene ontology analysis shows that 
PARROT affects the expression of genes involved in cell 
cycle regulation, cellular growth and proliferation as well 
as cellular movement (Figure 4A), in accordance with the 
phenotype observed following knock-down of PARROT 
in both HeLa and A549 cells.
To further explore the effect of PARROT on 
protein levels we used mass spectrometry to determine 
abundance and differential expression of the proteome 
following siRNA depletion of PARROT. Here, using 
SILAC (stable isotope labeling by amino acids in cell 
culture) control cells were labeled with heavy isotopes 
and the cells depleted of PARROT were labeled with light 
isotopes. Protein extracts were mixed in equal ratios and 
the intensities of both heavy and light labeled peptides 
were measured by mass-spectrometry. Analysis reveals 
that depletion of PARROT affects the levels of 73 proteins 
of which 22 are upregulated and 51 are downregulated. 
Furthermore, purifying phosphoproteins and subsequent 
identification of differentially phosphorylated proteins 
by mass spectrometry reveals that depletion of PARROT 
affects the phosphorylation status of 264 proteins: 98 are 
hyper-phosphorylated and 166 are hypo-phosphorylated. 
Gene ontology analysis shows that PARROT affects 
proteins involved in cell cycle regulation, cellular growth 
and proliferation as well as cellular movement on the 
level of protein synthesis as well as phosphorylation, in 
agreement with the results from RNA-seq data (Figure 
4B). 
Incorporating all large-scale data into an Ingenuity 
Pathway Analysis (IPA) predicts  c-Myc as a significant (p 
= 3.09x10-5) upstream regulator of the genes affected by 
Figure 2: PArrOt is primarily a cytoplasmic long non-coding rNA. A. Distribution of PARROT in the cytoplasm, nucleoplasm 
and chromatin. As controls for the cellular fractionation pre-gapdh and 7SL are shown. The average of 2-Ct ± s.d. are shown, n = 3. b. 
Snapshot from the genome browser showing the PARROT transcript in chromatin RNA-seq and polyA RNA-seq. c. In vitro translation 
assay. D. Polysome profile of HeLa cells. Polysomal distribution of GAPDH and PARROT RNAs was determined by isolating the RNA 
from each fraction collected from a 10-50% sucrose gradient. Percentage of mRNA level determined by qPCR in each fraction is shown.
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Figure 3: PArrOt regulates growth and translation. A. Knock-down of PARROT in HeLa cells with two different siRNAs. As 
a control, HeLa cells were transfected with a non-targeting control siRNA (NK). b. Crystal violet viability assay in HeLa cells transfected 
with either the control siRNA (NK) or depleted of PARROT for 72h. The average ± s.d. are shown, n = 5 (si1 p = 4.87581E-06, si2 p = 
1.58272E-05). c. Migration assay. A549 cells were transfected with either the control siRNA (NK), two different siRNAs against PARROT 
or SNAI1which was used as a positive control, and D. quantified using three independent experiments. E. Puromycin translation assay 
with western blot using a puromycin antibody. Shown are: Protein standard (PS), protein extracts from control HeLa cells not treated 
with puromycin (-ctrl), control HeLa cells treated with puromycin (+ctrl), and cells treated with puromycin and transfected with either 
control siRNA (NK) or two different siRNAs against PARROT for 72h. F) Ponceau S staining as the loading control and the bottom panel: 
quantification of puromycin incorporation in three independent experiments. (The average ± s.d. is shown; ** p < 0.01, * p < 0.05).
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the depletion of PARROT. Known Myc targets such as 
CDC34 (involved in cell death) [31], ROCK2 (involved 
in cellular adhesion, migration, apoptosis, differentiation) 
[32-34]; EPHA2 (migration, proliferation, adhesion, 
growth) [35]; RHOB (Ras family member involved 
in apoptosis, growth, proliferation, transformation, 
migration, adhesion) [36]; SLC7A5 (involved in growth 
and proliferation) [37]; DUSP5 (negatively regulates 
members of MAP kinase superfamily which are associated 
with cellular proliferation and differentiation) [38]; MIF 
(involved in proliferation, apoptosis, migration, aging and 
cell death) [39]; and FOSL1 (involved in proliferation, 
migration, motility, invasion, cell cycle progression, 
differentiation, apoptosis, etc.) [40, 41], are differentially 
expressed and/or phosphorylated following PARROT 
depletion (Figure 5A). We examined the direct effects of 
PARROT knock-down on c-Myc both at the RNA and 
protein levels. qPCR analysis reveals that the transcript 
level of c-Myc is decreased upon knock-down of PARROT 
(Figure 5B). In accordance with these results, the levels of 
both total c-Myc (Figure 5C) and phosphorylated c-Myc 
are decreased following knock-down of PARROT (Figure 
5D). The regulation of c-Myc as an important target of 
PARROT is in agreement with the phenotypes in cell 
growth and migration observed since c-Myc is a known 
regulator of cellular proliferation and growth as well as of 
migration [17, 18].
PArrOt is associated with proliferation in 
senescence and cancer
The effect on translation and the association to 
proliferation together with the regulation of c-Myc 
prompted us to look at biological scenarios where 
proliferation is changed. An expression analysis of 
PARROT across a panel of cell lines shows differential 
expression of PARROT between cell lines. PARROT 
is expressed at the highest level in human mammary 
epithelial cells (HMEC) (Figure 6A). HMECs are healthy, 
untransformed, human mammary epithelial cells that 
undergo replicative senescence, an irreversible arrest of 
cell growth, after approximately 14 passages [42]. HMECs 
from young, proliferative (passage 2) and senescent 
(passage 14) cells were analyzed for PARROT expression 
by RNA-sequencing (Figure 6B) and qPCR (Figure 
6C). As a marker of senescence we did western blot for 
p16 (Figure 6D). In accordance with the RNA-seq data, 
qPCR analysis shows that as HMECs grow older with 
passaging the expression of PARROT gradually decreases 
(Figure 6B and 6C). Knock-down of PARROT in HMECs 
decreases the cell growth significantly as we also observe 
in HeLa cells (Figure 6E), showing that PARROT is not 
only involved in proliferation of transformed cells, but has 
an effect on cell growth in non-transformed cells also.
In the other end of the spectrum of proliferation, 
analysis of 8 paired normal and tumor samples from 
stomach shows that PARROT is not expressed in 
healthy stomach cells of stomach cancer patients. In 
tumor samples, on the other hand, it is highly expressed 
compared to normal tissue from the same patients (Figure 
7A-7B). Furthermore, examination of the expression of 
c-Myc in these patients displays a similar trend, c-Myc is 
expressed at a significantly higher level in tumor samples 
than in normal paired tissue samples (Figure 7C). This 
observation supports our findings and further suggests that 
PARROT has an effect on proliferation that can lead to an 
oncogenic potential that is exerted via regulation of the 
c-Myc oncogene.
DIscUssION
The expression level of long ncRNAs is often very 
low and tissue-specific, properties that make the study 
Figure 4: PArrOt affects gene expression. A. Gene ontology analysis of genes differentially expressed upon knock-down of 
PARROT. b. Gene ontology analysis of differentially phosphorylated proteins upon knock-down of PARROT. 
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of their functionality challenging. We have used data for 
Pol(II) association to long ncRNA promoters in two well-
studied cell-lines, HeLa and HEK293 cells, to identify 
highly expressed long ncRNA with a pattern of differential 
expression between the cell-lines. We restricted the set 
of identified long ncRNAs by overlaying with data for 
differential expression of long ncRNAs in keratinocytes 
following differentiation, to reduce the number of 
Figure 5: PArrOt is an upstream regulator of c-Myc. A. Ingenuity network analysis showing Myc as the prime target of 
PARROT. Regulatory network based on RNA-seq data (upper panel) or phospho mass-spectrometry data (lower panel) b. qPCR showing 
the levels of processed c-Myc transcript in HeLa cells transfected with either the control siRNA (NK) or depleted of PARROT. The average 
± s.d. are shown, n = 3 (si1 p = 0.000541914, si2 p = 0.001295592). c.-D. Western blot of total c-Myc c. or phospho-form of c-Myc D. 
from protein extracts of Hela cells transfected with either the control siRNA (NK) or two different siRNAs against PARROT. 
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candidates and increase the likelihood of studying 
functional long ncRNAs [25]. The low expression of most 
long ncRNAs is believed to be a consequence of rapid 
degradation. Using promoter assays, we can show that 
the high expression of PARROT in HeLa cells is a direct 
consequence of a strong promoter activity, and that the 
absence of PARROT expression in HEK293 cells is not 
caused by increased degradation but simply reflects that 
the promoter is not active in HEK293 cells. We identify 
a short core promoter reflecting properties comparable to 
most protein coding gene promoters, and the expression 
of PARROT in tumor samples suggests a specific 
transcriptional activation causing the overexpression of 
PARROT.
Interestingly, PARROT is transcribed as a very 
long primary transcripts and only a relatively short 
sequence in the 5’ end is further processed by splicing 
to the cytoplasmic two-exon mature form, suggesting 
that PARROT could have both nuclear and cytoplasmic 
functions. This might reflect a significant difference 
between processing of some long ncRNAs compared to 
protein-coding genes.
IPA upstream pathway analysis of PARROT targets 
identified independently by RNA sequencing or mass 
spectrometry, suggested c-Myc as one of the important 
upstream regulators, suggesting that PARROT is an 
upstream regulator of c-Myc. This hypothesis is supported 
by a robust effect of PARROT knock-down on c-Myc both 
at the mRNA, protein and phosphorylation level of c-Myc.
The pronounced effects we observe on proliferation, 
migration and translation in HeLa, HMEC and A549 cells 
following knock-down of PARROT are recapitulating 
the phenotype that would be expected for a decreased 
expression or activity of c-Myc [17, 43], and suggests 
a general function of PARROT in mediating upstream 
regulation of c-Myc in both transformed and non-
transformed cells.
We can demonstrate an involvement of PARROT in 
senescence and cell proliferation in cancer that would be 
required for a regulator of c-Myc. We observe an increased 
expression of both c-Myc and PARROT in stomach cancer 
samples from eight patients analyzed by RNA sequencing. 
PARROT is dysregulated in 4 different types of cancer: 
BRCA (Breast Invasive Carcinoma), KIRC (Kidney Renal 
Figure 6: PArrOt is differentially expressed in senescence. A. RNA-seq data showing the expression of PARROT in different 
cell lines. b. Snapshot from the genome browser of RNA-seq data of HMECs cells in passage 2 and in passage 14. c. qPCR of PARROT 
in ageing HMECs. D. p16 western-blot in ageing HMECs. In C and D p refers to passage number. E. Crystal violet viability assay of 
HMECs cells in passage 5 of nontransfected cells (ctrl) or cells transfected with either control siRNA (NK) or two different siRNAs against 
PARROT for 72h. The average ± s.d. are shown, n = 5 (si1 p = 1.09588E-12, si2 p = 2.86182E-12).
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Clear Cell Carcinoma), LUAD (Lung Adenocarcinoma) 
and LUSC (Lung Squamous Cell Carcinoma) according 
to the lncRNome atlas (http://tcla.fcgportal.org). PARROT 
has previously been found to be associated with renal 
and lung adenocarcinoma [44] and could therefore be 
an important regulatory factor of the c-Myc pathway in 
several cancers as well as normal cells such as HMECs.
Several studies have shown that c-Myc can regulate 
the expression of long ncRNAs, and that some of these 
ncRNAs also participate in regulating the transcription of 
c-Myc target genes [19, 20, 22]. The promoters of long 
ncRNAs that are repressed by c-Myc have been shown to 
be more enriched for c-Myc binding sites than repressed 
mRNAs, suggesting a particularly important role for 
long ncRNAs in the Myc signaling network [21]. These 
long ncRNAs can act to regulate c-Myc targets and as 
oncogenes themselves promoting cellular proliferation and 
migration [19-22].
c-Myc directly binds to the promoter of H19 
activating its expression by recruiting a histone 
acetyltransferase. A reduction in clonogenicity and 
anchorage independent growth is observed upon depletion 
of H19 in both breast and lung cancer cells [45]. These 
results suggest that H19 acts downstream of c-Myc to 
promote tumorigenesis in breast and lung cancer cells.
Similarly, in gastric cancer c-Myc has been shown 
to activate the expression of colon cancer associated 
transcript 1 (CCAT1). Overexpression of CCAT1 leads to 
an increase in proliferation and migration of gastric cancer 
cells [46]. A longer isoform of the same transcript called 
CCAT1-L has been shown to regulate the expression of 
Myc in colon cancer. It is proposed that CCAT1-L enables 
the interaction between the enhancer and the c-Myc 
promoter through modulation of CTCF concentration 
thereby promoting tumorigenesis [47].
A highly expressed long RNA in gastric cancer 
called gastric carcinoma high expressed transcript 1 
(GHET1) also regulates c-Myc. This ncRNA enhances 
the stability and the expression of c-Myc by cooperating 
with insulin-like growth factor 2 mRNA binding protein 
1 (IGF2BP1) leading to an enforced physical interaction 
between IGF2BP1 and c-Myc RNA. Depletion of c-Myc 
reduces the ability of GHET1 to promote proliferation of 
cancer cells [48].
We observe that the spliced form of PARROT is 
localized to the cytoplasm. There is a decrease in c-Myc 
mRNA as well as protein levels upon siRNA-mediated 
knock-down of PARROT, suggesting a role of PARROT 
in regulating mRNA stability or translation of c-Myc. The 
long ncRNA PCAT-1 has been suggested to regulate the 
translation of c-Myc through disruption of miRNA binding 
to the Myc 3’ UTR and the long ncRNA GAS5 has been 
shown to bind the translation initiation factor eIF4E and 
specifically target c-Myc translation [22, 24]. Our findings 
that PARROT can orchestrate a group of genes regulated 
by c-Myc identifies an additional factor in this complex 
network with important implications for both normal 
and cancer cells and the understanding of the molecular 
mechanisms involved.
Further investigation is needed to shed light onto the 
Figure 7: PArrOt is upregulated in stomach cancer. A. Genome browser snapshot of RNA-seq in control or tumor stomach 
cancer sample. b. Expression (RNA-seq) of PARROT in control (N) and tumor (T) stomach cancer samples. c. Expression (RNA-seq) of 
c-Myc in control (N) and tumor (T) stomach cancer samples. B and C show expression of PARROT and Myc, respectively, as RPKM (reads 
per kilobase per million reads) as quantified from RNA-seq data.
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mechanism by which PARROT regulates c-Myc, which 
could reveal important mechanistic insight into how 
c-Myc is regulation modulated in both untransformed and 
transformed cells.
MAtErIALs AND MEtHODs
Pol(II) association analysis
Long ncRNAs differentially expressed upon 
keratinocyte differentiation were obtained from [25]. 
Publicly available ENCODE Chip-seq data for Pol(II) 
were used. Long ncRNAs and Pol(II) were intersected by 
the use of BEDTools [49].
cell culture
HeLa, HEK293 and A549 cells were cultured in 
complete DMEM medium (Gibco/LifeTechnologies, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum and penicillin-streptoMycin (Gibco). HMEC cells 
were cultured as previously described in a 1:1 mixture of 
MM4 and MCDB170 medium with of 5µg/ml of cholera 
toxin (Sigma), 5% AlbuMAX (Invitrogen) and 1µM 
oxytocin (Bachem) as described in [50]. All cells were 
cultured at 37 °C with 5% CO2. 
Luciferase assay
Promoter upstream region (166bp, 222bp, 
298bp and 404 bp) sequence located upstream of the 
PARROT TSS were cloned upstream of the luciferase 
into pGL3-basic vector (Promega). Primers used 
for amplification of the human genomic DNA with 
Phusion DNA polymerase (NEB) (Forward: 404bp- 
5’-TGAAGATCTCTGACCACCTGTTGAGCTGT-3’, 
298bp- 
5’-TGAAGATCTAGGAAATTGGTCAAGGTTGC-3’, 
223bp-5’-TGAAGATCTCCACTCA
GTTATTTTTGTCTCTCA-3’, 166bp- 
5’-TGAAGATCTAAGCTCCCAGAAATGTCAGC-3’; 
Reverse: 
5’-TGAAAGCTTCCACCCAGAGTCAAGGAGAC-3’) 
contain added BglII (NEB) and HindIII (NEB) restriction 
sites. Both the vector and the insert were digested with 
BglII and HindIII restriction enzymes to allow directional 
cloning.
HeLa and HEK293 cells (10,000 cells/well) were 
plated in 96-well white plates 24 h before transfection. 
Cells were co-transfected with 0.1 μg pGL3-basic-
promoter constructs and 0.02 μg of pRL-TK vector 
(Promega) using lipofectamine2000 (Invitrogen). 
Luciferase activity was measured 24 h after the 
transfection using the Dual-Luciferase Reporter Assay 
System kit (Promega) according to the manufacturer’s 
instruction. For data analysis, Firefly luciferase activity 
was normalized to that of Renilla luciferase. All 
transfections were carried out in triplicates at least three 
times.
In vitro translation assay
In vitro translation assay (Promega) was performed 
according to the manufacturer’s instruction.
cellular fractionation
RNA was extracted from cellular fractionsprepared 
from ~4 × 106 cells as described in [27].
crystal violet viability assay
HeLa or HMEC cells (10,000 cells/well) were plated 
in 96-well plates 24 h before transfection with siRNAs 
against PARROT or control siRNAs. Three days after the 
transfection cells where washed with PBS and fixed with 
methanol for 15min after which they were washed with 
water and stained with 0.1% crystal violet. After 20min 
cells were washed with water and dried. The following 
day 50 μl/well of 33% acetic acid was added and the 
absorbance at 590nm was measured. All transfections 
were carried out in triplicates at least three times.
Quantitative real-time Pcr
Total RNA was extracted from cells following 
the manufacturer’s instructions with TRIzol (Life 
Technologies). Reverse transcription was carried out with 
High Capacity RNA-to-cDNA Kit (Life Technologies) 
and qPCR was performed using the Fast SYBR Green 
Master Mix (Life Technologies) on a 7900HT Fast Real-
Time PCR System (Applied Biosystems, Foster City, 
CA, USA). The relative expression was calculated by 
normalizing to the Actin or GAPDH expression level as 
control housekeeping genes.
The following primers were used: PARROT 
(5’-CAGAACAGAGCCACCTCCAG-3’, 
5’-GCACCGTCTGTTGTTCATTC-3’), c-Myc 
(5’-GCTGCTTAGACGCTGGATTT-3’, 
5’-CCTCCTCGTCGCAGTAGAAA-3’), 
GAPDH (5’-GCTCTCTGCTCCTCCTGT TC-
3’, 5’-ACGACCAAATCCGTTGACTC -3’),and 
β-actin (5′-CGACAGGATGCAGAAGGAG-3′, 
5′-GTACTTGCGCTCAGGAGGAG-3′).
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rNA interference
dsiRNA oligos from 
IDTDNA (siRNA1 PARROT: sense 
5’-GAAUGAAAGCACAGCACCAUCCUGGAA-3’, 
antisense 
5’-CCAGGAUGGUGCUGUGCUUUCAUTC-3’; 
siRNA2 PARROT: sense 5’- 
GCUGAAUCAAGAUGCUGACUUCAGCAC-3’, 
antisense 
5’-GCUGAAGUCAGCAUCUUGAUUCAGC-3’) were 
used. As a negative control we used DS NC1 (IDT DNA).
Cells were transfected at a final dsiRNA concentration 
of 50 nM using Lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s protocol. Cells were 
collected 24 h or 48h after the transfection for RNA 
isolation and 72 h after transfection for western blot 
analysis.
sucrose gradient fractionation and rNA isolation
Cytoplasmic lysates of HeLa cells were prepared 
and subjected to centrifugation through linear sucrose 
gradients (10-50% sucrose) essentially as described 
previously [51]. siRNA transfected cells (3x 10cm plates 
per condition) were rinsed and scraped in ice-cold PBS 
containing 100µg/mL cycloheximide. All subsequent 
steps were performed in ice-cold conditions. Cells were 
pelleted and resuspended in extraction buffer (20 mM 
Tris-HCl, pH 8.0, 140 mM KCl, 0.5 mMDTT, 5 mM 
MgCl2, 0.5% Nonidet-P40, 0.1 mg/ml cycloheximide, and 
0.5 mg/ml heparin), incubated 10 min on ice and clarified 
by centrifugation for 10 min at 12000g. Approximately 
400µL of supernatant was layered onto a 12-ml linear 
sucrose gradient (10-50% sucrose (w/v) in detergent free 
extraction buffer) and centrifuged at 4 °C in an SW40Ti 
rotor (Beckman, Palo Alto, CA) at 35,000 rpm without 
brake for 120 min. The gradients were collected into 12 
fractions (1ml each), and absorbance profiles at 260 nm 
were recorded (ISCO, UA-6 detector). 0.1 volume of 3 M 
sodium acetate (pH 5.2) and 1 volume of isopropyl alcohol 
were added to the probes for overnight precipitation 
at −20 °C. RNA was purified using total RNA isolation 
kit (Nucleospin RNA II, Macherey & Nagel) following 
the manufacturer’s protocol. RNA concentration was 
determined, and the samples were stored at −80 °C.
Puromycin translation assay
Three days after the knockdown 1μM puromycin 
was added to the cells for 30 min. Cells were harvested 
in RIPA buffer, sonicated and boiled for 5min at 95°C in 
Laemmli buffer. 15μg of protein was loaded on a 4-12% 
Bis-Tris gradient gel (NuPAGE Novex) and transferred 
onto a PVDF membrane. Membrane was blocked in 5% 
milk and incubated overnight at 4°C with 1μg/ml anti-
puromycin antibody (Kerafast). Membrane was washed, 
incubated with secondary HRP conjugated antibody and 
developed using ECL reagent (Pierce). To make sure that 
the equal amount of protein from puromycin treated cells 
was loaded on the gel the membrane was stained with 
Ponceau S protein dye prior to blocking.
Migration assay
A549 cells were seeded in a 6 well plate (100000 
cells/well) 4 h before transfection with siRNAs against 
PARROT, SnaiI or control siRNAs. 48 hours later cells 
were starved for 24h in a DMEM medium without FCS 
after which 50000 cells were added in DMEM medium 
without FCS to a migration chamber placed in a well of 
24 well plate containing 750 μl of DMEM with FCS. 14 
hours later cells where washed with PBS and cells that did 
not migrate were swiped. Cells that migrated were fixed 
with methanol for 15min after which they were washed 
with water and stained with 0.1% crystal violet. After 
20min cells were washed with water, dried and number of 
migrating cells quantified.
Western blot
Cells were harvested in RIPA buffer, sonicated 
and boiled for 5min at 95°C in Laemmli buffer. 15μg 
of protein was loaded on a 4-12% Bis-Tris gradient 
gel (NuPAGE Novex) and transferred onto a PVDF 
membrane. Membrane was blocked in 5% milk and 
incubated overnight at 4°C with total c-Myc (Santa Cruz 
Biotechnology sc-40), phosphor-c-Myc (Abcamab32029)
or p16 (Santa Cruz Biotechnology sc-468) antibody. 
Membrane was washed, incubated with secondary HRP 
conjugated antibody and developed using ECL reagent 
(Pierce).
rNA sequencing
Total RNA was extracted using TRIzol (Life 
Technologies). RNAseq libraries were prepared with the 
TruSeq RNA Sample Preparation Kit v2. Sequencing 
was performed on a HiSeq 2000 instrument (Illumina, 
San Diego, CA, USA) using paired-end sequencing (2 × 
50 bp). Data was analyzed with the TRUP pipeline [52]. 
Differential expression analysis was preformed in edgeR 
Bioconductor package [53]. The cutoff for differentially 
expressed genes was set at FDR < 0.05. The RNA-seq 
data are deposited in GEO with the accession number 
GSE69842.
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Mass-spectrometry
HeLa cells used for MS were grown in SILAC 
medium.They were lysed and digested by trypsin under 
denaturing conditions as previously reported [55]. 
Peptides were purified with C18 columns and fractionated 
by a strong cation exchange (SCX, Polysulfoethyl A, 200 
x 9.4 mm, 5µm 200Å, PolyC, Columbia, MA) column, 
5% of resulting peptides in each of the 11 fractions were 
used for proteome profiling. The remaining peptides 
were further enriched for phospho peptides by TiO2 (GL 
Sciences, Japan) columns [55]. Each sample fraction was 
dissolved in 3 µL of 5% ACN and 2% FA and analyzed 
by LC-MS/MS. LC−MS/MS was carried out by nanoflow 
reverse phase liquid chromatography (Dionex Ultimate 
3000, Thermo Scientific, Waltham, MA) coupled online 
to a Q-Exactive Plus Orbitrap mass spectrometer (Thermo 
Scientific) as described previously [54]. Raw MS data 
were processed with MaxQuant v1.4.1.2 [56] and searched 
against the human proteome database UniProtKB with 
81.194 entries, released in 02/2012. A false discovery 
rate (FDR) of 0.01 for proteins and peptides and a 
minimum peptide length of 7 amino acids were required. 
A maximum of two missed cleavages was allowed for 
the tryptic digest. Following SILAC modifications were 
used: 13C6
15N4-arginine and 
13C6
15N2-lysine. Cysteine 
carbamidomethylation was set as fixed modification, while 
N-terminal acetylation and methionine oxidation were 
set as variable modifications in all runs, phosphorylation 
of serine, threonine and tyrosine were set as variable 
modifications in the according enriched fractions.In 
order to filter for differentially regulated proteins or 
phosphoproteins we set the cutoff for the ratio of light 
(knock-down treatment) to heavy (control) to be > 1.2 for 
upregulated and < 0.8 for downregulated. Additionally, 
we also required that the ratio of knock-down/control to 
be > 1.2 or < 0.8 compared to the ratio of control knock-
down(NK)/control.
Gene ontology analysis
The functional analysis and networks were 
generated through the use of QIAGEN’s Ingenuity 
Pathway Analysis (IPA, QIAGEN Redwood City, www.
qiagen.com/ingenuity).
statistics
Statistical analysis was performed using two-tailed 
Student’s T-test. 
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